NovoCure is leaving the single-indication era. The second quarter is the first full commercial stretch in which Tumor Treating Fields, the wearable electric-field therapy sold under the Optune brands, is generating prescriptions in brain, lung, and pancreatic tumors at once. Frank Leonard, elevated from president to chief executive in December, is treating that shift as a harvest of approved labels rather than another round of new cancer-type bets. The debate is whether the new indications can become a second earnings engine before glioblastoma growth cools.
The print finally shows operating leverage. Net revenue reached $184 million, a sixteen percent rise, while adjusted earnings before interest, taxes, depreciation, amortization and share-based pay flipped to an $11 million profit. That swing is the first positive adjusted result since calendar two thousand twenty four, and it is why management lifted both the full-year revenue band and the adjusted-earnings range. The catch is mix. Optune Gio for glioblastoma still supplies almost all of the cash, and the two newer devices together contributed only $7 million. A one-time tariff refund and a handful of collection benefits flattered both margin and the top line, so the quality of the beat is thinner than the headline.
Active patients crossed five thousand for the first time, with Optune Pax already at a few hundred users after a February approval and a late June European mark. Japan started reimbursing Optune Lua in March and already accounts for most of the new lung-cancer installs. What the next several quarters resolve is whether pancreatic repeat prescribing and payer coverage convert a clinically approved device into a scaled revenue line, or whether Tumor Treating Fields remains a glioblastoma annuity with two small, reimbursement-constrained add-ons.